← Back to Search

Kinase Inhibitor

Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation

N/A
Waitlist Available
Research Sponsored by Loxo Oncology, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group

Summary

Expanded access for participants with cancer with RET activation who are ineligible for an ongoing selpercatinib (also known as LOXO-292) clinical trial or have other considerations that prevent access to selpercatinib through an existing clinical trial. The treating physician/investigator contacts Lilly when, based on their medical opinion, a patient meets the criteria for inclusion in the expanded access program.

Eligible Conditions
  • Pancreatic Cancer
  • Solid Tumors
  • Breast Cancer
  • Non-Small Cell Lung Cancer
  • Thyroid Cancer
  • Medullary Thyroid Cancer
  • Colon Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Find a Location

Who is running the clinical trial?

Loxo Oncology, Inc.Lead Sponsor
71 Previous Clinical Trials
11,060 Total Patients Enrolled
Eli Lilly and CompanyIndustry Sponsor
2,680 Previous Clinical Trials
3,466,384 Total Patients Enrolled
Contact Lilly at 1-800-LillyRx (1-800-545-5979)Study DirectorEli Lilly and Company
11 Previous Clinical Trials
419 Total Patients Enrolled
~233 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top